Commonwealth legislation

Therapeutic Goods (Listing) Notice 2012 (No. 1)

RepealedCTH

This Act has been repealed and is no longer in force. It is retained for historical reference.

Jurisdiction

Commonwealth

Collection

legislative instrument

Plain English Summary

2/10 complexity

This notice temporarily allows specific molybdenum supplements to be sold in Australia as listed therapeutic goods (a regulatory category for lower-risk medicines like vitamins and minerals).

What it covers: Preparations containing sodium molybdate dihydrate (a form of the essential mineral molybdenum).

Key restrictions:

Oral use only — the product must be swallowed (not injected or applied to skin)
Dosage limit — no more than 125 micrograms of molybdenum per daily dose

Why it matters: Therapeutic goods normally require entry in the Australian Register of Therapeutic Goods (ARTG) before they can be legally supplied. This notice acts as a temporary entry for these specific molybdenum products while permanent regulations are being updated. Once those permanent regulations take effect, this notice automatically ceases to apply.

JSON API Health / NDIS / medicines

Deep dive

Want the full deep dive?

Zoe can write the in-depth analysis on top of the summary above: how it works, who it affects and what each part actually does.

Current sections

Direct links to the current provisions in Therapeutic Goods (Listing) Notice 2012 (No. 1).

Therapeutic Goods (Listing) Notice 2012 (No. 1)

Therapeutic Goods Act 1989

Therapeutic Goods (Listing) Notice 2012 (No. 1)

I, BRIAN RICHARDS, National Manager (Acting) of the Therapeutic Goods Administration, delegate of the Minister for Health for the purposes of subsection 9A(5) of the Therapeutic Goods Act 1989 (the Act) and acting under that provision, require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods (the Register) for listed goods:

preparations, for the purpose of Item 3, Part 1 of Schedule 4 to the Therapeutic Goods Regulations 1990 (the Regulations), that contain ‘sodium molybdate dihydrate’ as a therapeutically active ingredient, subject to the following conditions:
the preparations are for oral use only; and
the preparations provide not more than 125 μg of molybdenum per daily dose.

This Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.

Pursuant to subsection 9A(6) of the Act, this Notice ceases to have effect on the day that amendments to the Regulations come into effect to require inclusion of the therapeutic goods listed in this Notice in the part of the Register for listed goods.

Dated this 1st day of May 2012

(signed by)

Brian Richards

Delegate of the Minister for Health

Source text

Sourced from the Federal Register of Legislation (legislation.gov.au), CC BY 4.0.

1 Therapeutic Goods (Listing) Notice 2012 (No. 1)

Therapeutic Goods Act 1989

Therapeutic Goods (Listing) Notice 2012 (No. 1)

preparations, for the purpose of Item 3, Part 1 of Schedule 4 to the Therapeutic Goods Regulations 1990 (the Regulations), that contain ‘sodium molybdate dihydrate’ as a therapeutically active ingredient, subject to the following conditions:
the preparations are for oral use only; and
the preparations provide not more than 125 μg of molybdenum per daily dose.

This Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.

Dated this 1st day of May 2012

(signed by)

Brian Richards

Delegate of the Minister for Health